Background. The aim of this study was to assess the efficacy of ceftriaxone and benzathine penicillin G (BPG) in nonpregnant, immunocompetent adults with early syphilis because there is a lack of clinical evidence supporting ceftriaxone as an alternative treatment for early syphilis without an human immunodeficiency virus coinfection.
Syphilis is a sexually transmitted disease caused by Treponema pallidum [1] . In recent decades, syphilis-related morbid conditions have dramatically increased in China and are becoming both a burden and a threat to public health. The total reported syphilis rate in China was 11.7/100 000 in 2009 [2] and 32.9/100 000 in 2013 [3] . This disease has challenged scientists and clinicians since its first appearance in the late 1400s, and the best practices for its management remain controversial.
Guidelines for defining and treating syphilis vary throughout the world. In North American and European guidelines, a single intramuscular administration of 2.4 million units (MU) of benzathine penicillin G (BPG) is recommended for treating early syphilis [4, 5] . In contrast, the recommended therapy for early syphilis in China is 2.4 MU of BPG administered intramuscularly once per week for 2 weeks [6] . BPG has been considered the standard treatment for early syphilis since it was first used for this indication in 1943 [7] . However, both shortage of BPG worldwide and patients who are allergic to penicillin present a major challenge [8] . Moreover, BPG is considered ineffective for neurosyphilis treatment because it does not lead to detectable levels of penicillin in the cerebrospinal fluid (CSF) [9] .
There are many reasons that patients cannot use penicillin to treat syphilis, so several alternative therapies were suggested, including doxycycline and ceftriaxone. There were no standardized criteria to choose alternative therapies. Several studies had showed the effectiveness of doxycycline in treating early syphilis, where retreatment rates are slightly higher in early syphilis than with penicillin regimens [10] . The response rate was 63.4%-92.4% in early syphilis in several studies [11] [12] [13] . There are circumstances under which doxycycline cannot be used, notably in pregnancy.
As another alternative therapy for syphilis, ceftriaxone has shown antitreponemal activity in animal models, is well tolerated, penetrates the central nervous system (CNS), and has a long half-life that is suitable for once-daily dosing [14, 15] .
Several studies have shown its effectiveness in treating neurosyphilis and primary and secondary syphilis in special populations, such as patients with human immunodeficiency virus (HIV)-infected, pregnant patients and alcoholic patients [14, 16, 17] . There is no report elucidating the sensitivity of T. pallidum to ceftriaxone in China, but several studies have evaluated the clinical efficacy of ceftriaxone for treating syphilis at the small scale [18, 19] . However, there is a lack of clinical evidence supporting ceftriaxone as an alternative treatment for early syphilis without an HIV coinfection. Thus, more studies on its efficacy under these circumstances are needed.
A randomized, open-label controlled study was designed to compare 1.0 g of ceftriaxone administered intravenously daily for 10 days and 2 doses of 2.4 MU of BPG administered intramuscularly at weekly intervals to treat nonpregnant, immunocompetent patients with early syphilis.
MATERIALS AND METHODS

Study Population
HIV-negative, nonpregnant, adult patients with untreated early syphilis were enrolled in the study. The disease stage classification was considered early when the patient presentation included the following features: (1) primary syphilis: dark-field T. pallidum-positive or rapid plasma reagin (RPR)-positive test results confirmed by the T. pallidum particle agglutination (TPPA) test, positive genital ulcers or chancres, and adenopathy near the primary infection site; (2) secondary syphilis: RPR-and TPPA-positive test results and classic palmar/plantar rash, condylomata lata, and mucocutaneous patches; and (3) early latent syphilis: seroreactivity without other evidence of primary or secondary syphilis and either negative syphilis serological results within the past 2 years or a recent sex partner with documented primary, secondary, or early latent syphilis. Subjects were excluded from the study if they had a positive skin-test reaction to the penicillin or ceftriaxone antigen or a history of penicillin or ceftriaxone allergy. The selection of BPG or ceftriaxone therapy was randomized.
Study Protocol
Subjects were enrolled in 4 hospitals in Jiangsu Province, including the Institute of Dermatology and Skin Hospital of Chinese Academy of Medical Science, Northern Jiangsu People's Hospital, the First People's Hospital of Lianyungang, and the Affiliated Hospital of Xuzhou Medical University, from November 2013 through November 2015. The study protocol and consent form have been approved by the institutional review boards from all 4 hospitals. All patients provided written consent to receive treatment and provide serum samples during the follow-ups. All clinical data were collected by the physicians managing the patients. The patients were randomly assigned to be treated with either ceftriaxone (1.0 g, given intravenously once daily for 10 days) or BPG (2.4 MU, given intramuscularly once weekly for 2 weeks). Serum RPR and TPPA results were determined at baseline, at 14 days, and at 3, 6, 9, and 12 months for all patients.
Study Design and Statistical Analysis
All follow-up biological results were collected for analysis. A serological response was defined as a ≥4-fold decline in the initial serum RPR titer within 6 months of treatment [5] . Because 4-fold drop at 12 months was considered an adequate serological response for early latent syphilis, mentioned in the Canadian guidelines on sexually transmitted infections [20] , a ≥4-fold decline in RPR titers at the 6-and 12-month follow-up visits were set as primary and secondary end points, respectively. Treatment failure was defined as a ≥4-fold increase in the titer, and serofast was defined as a ≤2-fold titer decrease or increase within 12 months after therapy [5] .
We hypothesized that the ceftriaxone regimen was noninferior to BPG in nonpregnant, immunocompetent patients with early syphilis. The noninferiority in terms of the serological response rate after ceftriaxone therapy relative to that of BPG therapy would be supported if the lower boundary of the 2-sided 95% confidence interval (1-sided α = -0.025; β = .10) for the difference in the serological response rates between the 2 groups was at least -0.05 (that is, the noninferiority margin was set to 5%).
Differences in categorical variables were compared using the χ 2 test. As continuous variables, changes in serum RPR titers, which were used to define the serological responses, were compared using the Mann-Whitney test. The median time to attain a serological response in responsive patients was estimated using the Kaplan-Meier method and compared using the logrank test. Cox regression analyses were used to assess the influence of age, sex, initial RPR titers, stage of early syphilis and Jarisch-Herxheimer (J-H) reaction on serological response. The J-H reaction is defined as an acute febrile reaction frequently accompanied by headache, myalgia, fever, and other symptoms that can occur within the first 24 hours after the initiation of any therapy for syphilis [15] . Differences were considered statistically significant at P < .05 (2-sided). Data were analyzed using SPSS, version 18.0 (SPSS).
RESULTS
Selection of Eligible Patients
A total of 340 patients with early syphilis were identified between 2013 and 2015. Of these, 39 patients were excluded, and the remaining 301 were enrolled in the study. The 39 excluded patients were treated with doxycycline. Of the enrolled patients, 150 were treated with ceftriaxone, and 151 with BPG ( Figure 1 ). Syphilis had been diagnosed for the first time in all patients.
Eleven patients (primary syphilis with chancres) in the 2 treatment groups (7 in the ceftriaxone and 4 in the BPG group) had negative baseline serum RPR titers, and 60 patients (31 in the ceftriaxone and 29 in the BPG group) had no follow-up data. The rates of patients without follow-up were 21.7% (31 of 143) and 19.7% (29 of 147) in the ceftriaxone and BPG groups, respectively. There was no significant difference in the number of patients lost to follow-up between the 2 treatment groups (P = .68).
Clinical and Serological Follow-Up
The main characteristics of the 230 subjects who completed follow-up visits are shown in Table 1 . There were no significant differences between the 2 treatment groups in age, sex, initial RPR titers, or heterogeneity of early syphilis stages (P > .05).
The median follow-up period was 9 months. There were no differences in the numbers of patients with each type of syphilis between the 2 treatment groups (P = .22). The probable J-H reaction rate was 41.1% in the ceftriaxone and 31.4% in BPG group (P = .13). Skin lesions disappeared within a month of the treatments for all follow-up patients. No patients reported serious adverse events, and adverse effects related to study drugs, other than J-H reaction, were not observed. The use of other antibiotics during the study follow-up period was not monitored.
We assessed improvements in serum RPR titers by comparing the baseline values with those at the different follow-up times ( Table 2) . The rates of serological responses in both treatment arms rose as the time passed by. The serological response was observed in 90.2% in the ceftriaxone and 78.0% in the BPG group (P = .01) after 6 months of follow up, and 92.0% and 81.4%, respectively (P = .02), after 12 months. There was no significant difference between treatment groups in patients with primary or early latent syphilis (P > .05), but among patients with secondary syphilis the difference Abbreviations: BPG, benzathine penicillin G; RPR, rapid plasma reagin.
was highly significant (95.8% vs 76.2% at 6 months, P < .01) ( Table 3) . Because a decline in the serum RPR titer may depend on the initial titer and the stage of early syphilis [21] , the initial RPR titers and the improvements in serum RPR titers for different stages were analyzed. At 12 months after therapy, a serological response was observed in 82.8% of participants with baseline RPR titers ≤1:8, and in 87.8% participants with titers >1:8 (P = .33). However, serological responses of primary syphilis, secondary syphilis, and early latent syphilis after 12 months of treatment were 100%, 87.4%, and 72%, respectively, which meant significant differences in serological responses between different stages (P < .01).
Because high serum RPR titers probably decrease more rapidly than low titers [21, 22] , the time to achieve serological response was analyzed. No significant difference was found in the delay before a serological response between the 2 groups (log-rank test, P = .29) (Figure 2) . Meanwhile, whether other factors (age, sex, initial RPR titer, syphilis stage, and J-H reaction) had an influence on the serological response of syphilis was also evaluated (Table 4 ). The stage of syphilis was associated with the serological response, especially when comparing early latent syphilis with primary syphilis (P = .02). Moreover, the J-H reaction was positively related to the serological response of syphilis (P = .03).
In all, 15 patients were determined to have a serofast status after the 12-month follow-up; 6 were in the ceftriaxone group, and 9 were in the BPG group. The serofast rate was not correlated with the type of treatment (P = .49). One case of serological failure was observed in the BPG arm. Fifteen patients (12 in the BPG and 3 in the ceftriaxone arm) had a documented ≥4-fold decline in RPR with a subsequent ≥4-fold increase. In 2 of these 15 patients, the increase was due to reinfection, because their RPR had turned to negative at 6-month visit. Among the left 13 patients, 1 patient rejected retreatment, and 12 received repeated treatment with BPG (2.4 MU, given intramuscularly once weekly for 3 weeks) or ceftriaxone (1.0-2.0 g, given intravenously once daily for 10-15 days).
DISCUSSION
The incidence of syphilis is increasing dramatically in many developing countries, predominantly in China. Although the definitions of and treatment guidelines for syphilis vary throughout the world, the treatment of early syphilis has changed little over the past few decades [5, 15] . BPG remains the recommended global therapy for early syphilis. However, up to 10% of individuals cannot be treated with penicillin because of allergic reactions [23] or a worldwide penicillin shortage, and treatment failures or relapse can occur [24] . Therefore, there is an unmet need for novel treatment options.
Most patients allergic to penicillin can tolerate cephalosporin. Studies of in vitro sensitivity have shown that the minimal inhibitory concentration of ceftriaxone for T. pallidum is very low, approximately 0.0006 µg/mL [25] . Moreover, a daily 1.0-g ceftriaxone dose achieves levels well above the minimal inhibitory concentration. Zhou et al [26] reported that ceftriaxone was effective in pregnant patients with syphilis who showed an allergic reaction to penicillin. Psomas et al [27] evaluated the efficacy of ceftriaxone as an alternative regimen for early syphilis in HIV-infected patients. However, to date, compared with the penicillin therapy, clinical studies on the efficacy of ceftriaxone for treating early syphilis are rare.
A meta-analysis of the effect of ceftriaxone compared with that of penicillin for the treatment of early syphilis showed that the 12-month response rates were 83% (73 of 88) and 71% (63 of 89), respectively, in the ceftriaxone and BPG groups [24] . Furthermore, most reports evaluating the efficacy of ceftriaxone for the treatment of syphilis do so in HIV-infected patients with or without neurosyphilis [24, 28] . Ceftriaxone was found to effectively improve CSF markers for neurosyphilis and was probably a superior treatment, given the decrease in serum RPR titers [28] . However, there are few prospective studies on the efficacy of ceftriaxone-treated, nonpregnant, immunocompetent patients with early syphilis.
In the present trial, the effectiveness of daily ceftriaxone administration for 10 days and weekly BPG administration for 2 weeks were compared in terms of decreases in nontreponemal antibody titers in nonpregnant, immunocompetent patients with early syphilis. At both 6-and 12-month follow-up visits, the rate of serological response was significantly higher in the ceftriaxone group than in the BPG group among patients with secondary syphilis, but not among those with primary or early latent syphilis (P < .01) ( Table 3) .
The results of the present study may be contrary to most conclusions of recent studies, in which the effect of ceftriaxone was equal to that of BPG in the treatment of several types of syphilis [17, 27, 28] . As mentioned above, the patients enrolled in those studies were coinfected with HIV with or without neurosyphilis, the clinical patient data were collected in single centers, and the sample sizes were very small. Moreover, the treatment administration was not randomized, and there was no standardized ceftriaxone dose. These factors may lead to biased conclusions. To avoid these issues, the present study was designed to be a multicenter, randomized, open-label investigation with a fixed dose and course of ceftriaxone in nonpregnant, immunocompetent patients with early syphilis. Thus, the current study has greater power (93%) for determining the efficacy of treatment with ceftriaxone compared with that of BPG in patients with early syphilis.
In the present study, most subjects showed a serological response <6 months after the completion of therapy. A higher probability of serological responses for patients at an earlier stage of infection was also observed. Participants with primary syphilis would show serological responses earlier than those with early latent syphilis (P = .02) (Table 4) . Notably, the better treatment response of subjects with secondary syphilis in the ceftriaxone group may be due to the infection of the CNS by T. pallidum, which is common in early syphilis [29] . In present study, whether asymptomatic CNS infection was more common in secondary syphilis was unknown, because lumbar punctures were not performed in those patients.
Reportedly, up to 30%-40% of patients with early syphilis exhibit evidence of CNS invasion by T. pallidum [9, 30] . Marra et al [25] reported that ceftriaxone achieved higher CSF concentrations than penicillin did. Therefore, ceftriaxone might be a good option for treating CNS T. pallidum infections. Ceftriaxone is reportedly effective for all presentations of neurosyphilis, including asymptomatic cases [17, 27, 31] . Maybe this was why ceftriaxone resulted in better serological responses than BPG in the current study. It is worth mentioning that for primary syphilis, serological responses rates were 100% in both groups, meaning that BPG should be first-line treatment of primary syphilis when considering efficacy and cost.
The J-H reaction is more likely to occur in patients with early syphilis. The serological response was associated with the occurrence of a J-H reaction (P = .03), indicating that patients exhibiting J-H reactions after treatment might respond serologically earlier than those without J-H reactions. Although several positive results were found in the present study, the limitations of the investigation should be mentioned. First, this study is limited by the 12-month follow-up period and by the missing data for some of the follow-up visits. If the follow-up period were longer, further research could be performed on the serofast population. Second, lumbar punctures were not performed in subjects with a serofast status. Finally, in contrast with BPG treatment, ceftriaxone is better for secondary syphilis with asymptomatic CNS infection, syphilis in special populations, such as HIV-infected or pregnant patients, and syphilis after failed BPG treatment. However, the exact dose, frequency, and treatment course of ceftriaxone recommended for early syphilis differ across many countries' guidelines [9] . The present study observed only 1 fixed dose and treatment course for ceftriaxone. Daily ceftriaxone administration via intravenous injections increased both the total treatment cost and the level of inconvenience.
Based on our findings, the ceftriaxone regimen was noninferior to the BPG regimen in nonpregnant, immunocompetent patients with early syphilis. Because of its cost, ease of administration, and narrow spectrum, BPG should still be preferred for treating patients with primary or early latent syphilis. Moreover, patients who experience a J-H reaction after treatment may respond serologically earlier than those who do not. Furthermore, whether ceftriaxone at a daily dose of 1.0 g administrated intravenously for 10 days could be a preferred alternative treatment of secondary syphilis needs to be determined based on data from future prospective studies. 
